Human antimicrobial peptide LL-37 contributes to Alzheimer's disease progression

Mol Psychiatry. 2022 Nov;27(11):4790-4799. doi: 10.1038/s41380-022-01790-6. Epub 2022 Sep 22.

Abstract

As a prime mover in Alzheimer's disease (AD), microglial activation requires membrane translocation, integration, and activation of the metamorphic protein chloride intracellular channel 1 (CLIC1), which is primarily cytoplasmic under physiological conditions. However, the formation and activation mechanisms of functional CLIC1 are unknown. Here, we found that the human antimicrobial peptide (AMP) LL-37 promoted CLIC1 membrane translocation and integration. It also activates CLIC1 to cause microglial hyperactivation, neuroinflammation, and excitotoxicity. In mouse and monkey models, LL-37 caused significant pathological phenotypes linked to AD, including elevated amyloid-β, increased neurofibrillary tangles, enhanced neuronal death and brain atrophy, enlargement of lateral ventricles, and impairment of synaptic plasticity and cognition, while Clic1 knockout and blockade of LL-37-CLIC1 interactions inhibited these phenotypes. Given AD's association with infection and that overloading AMP may exacerbate AD, this study suggests that LL-37, which is up-regulated upon infection, may be a driving force behind AD by acting as an endogenous agonist of CLIC1.

MeSH terms

  • Alzheimer Disease* / metabolism
  • Alzheimer Disease* / pathology
  • Amyloid beta-Peptides / metabolism
  • Animals
  • Cathelicidins* / metabolism
  • Cathelicidins* / pharmacology
  • Chloride Channels* / metabolism
  • Humans
  • Mice
  • Microglia / metabolism

Substances

  • Amyloid beta-Peptides
  • Cathelicidins
  • Chloride Channels
  • CLIC1 protein, human